Cargando…

Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients

PURPOSE: To compare the clinical efficacy between peramivir and oseltamivir in hospitalized patients with influenza. PATIENTS AND METHODS: Retrospective cohort study examined data from 542 adult patients with laboratory-confirmed seasonal influenza hospitalized in five teaching hospitals and one secon...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jin Seo, Lee, Mi Suk, Park, Yoonseon, Lee, Jacob, Joo, Eun-Jeong, Eom, Joong Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245436/
https://www.ncbi.nlm.nih.gov/pubmed/32547116
http://dx.doi.org/10.2147/IDR.S247421
_version_ 1783537758679072768
author Lee, Jin Seo
Lee, Mi Suk
Park, Yoonseon
Lee, Jacob
Joo, Eun-Jeong
Eom, Joong Sik
author_facet Lee, Jin Seo
Lee, Mi Suk
Park, Yoonseon
Lee, Jacob
Joo, Eun-Jeong
Eom, Joong Sik
author_sort Lee, Jin Seo
collection PubMed
description PURPOSE: To compare the clinical efficacy between peramivir and oseltamivir in hospitalized patients with influenza. PATIENTS AND METHODS: Retrospective cohort study examined data from 542 adult patients with laboratory-confirmed seasonal influenza hospitalized in five teaching hospitals and one secondary hospital between August 2017 and May 2018. The main outcome was the defervescence rate within 3 days from the first administration of peramivir or oseltamivir. The secondary outcomes were mortality and duration of hospitalization/intensive care unit (ICU) stay. RESULTS: Of the 542 enrolled patients, 251 were administered the standard dose of peramivir (300 mg, single dose), 42 were administered peramivir at doses exceeding 300 mg, and 249 were administered oseltamivir (75 mg, twice daily for 5 days). There were more ICU and pneumonia cases and older patients in the peramivir group, especially the high-dose group. The Charlson comorbidity index (CCI) scores were similar among the three groups. There were no significant differences in defervescence rates within 3 days between the three groups. The mortality and duration of hospital and ICU stays also did not differ significantly. The factors associated with 30-day mortality were ICU admission, high CCI score, and pneumonia. CONCLUSION: Treatment of influenza with either peramivir or oseltamivir in hospitalized adults resulted in generally similar clinical outcomes. Peramivir treatment showed good clinical response in influenza patients with pneumonia or admitted to the ICU.
format Online
Article
Text
id pubmed-7245436
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72454362020-06-15 Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients Lee, Jin Seo Lee, Mi Suk Park, Yoonseon Lee, Jacob Joo, Eun-Jeong Eom, Joong Sik Infect Drug Resist Original Research PURPOSE: To compare the clinical efficacy between peramivir and oseltamivir in hospitalized patients with influenza. PATIENTS AND METHODS: Retrospective cohort study examined data from 542 adult patients with laboratory-confirmed seasonal influenza hospitalized in five teaching hospitals and one secondary hospital between August 2017 and May 2018. The main outcome was the defervescence rate within 3 days from the first administration of peramivir or oseltamivir. The secondary outcomes were mortality and duration of hospitalization/intensive care unit (ICU) stay. RESULTS: Of the 542 enrolled patients, 251 were administered the standard dose of peramivir (300 mg, single dose), 42 were administered peramivir at doses exceeding 300 mg, and 249 were administered oseltamivir (75 mg, twice daily for 5 days). There were more ICU and pneumonia cases and older patients in the peramivir group, especially the high-dose group. The Charlson comorbidity index (CCI) scores were similar among the three groups. There were no significant differences in defervescence rates within 3 days between the three groups. The mortality and duration of hospital and ICU stays also did not differ significantly. The factors associated with 30-day mortality were ICU admission, high CCI score, and pneumonia. CONCLUSION: Treatment of influenza with either peramivir or oseltamivir in hospitalized adults resulted in generally similar clinical outcomes. Peramivir treatment showed good clinical response in influenza patients with pneumonia or admitted to the ICU. Dove 2020-05-19 /pmc/articles/PMC7245436/ /pubmed/32547116 http://dx.doi.org/10.2147/IDR.S247421 Text en © 2020 Lee et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lee, Jin Seo
Lee, Mi Suk
Park, Yoonseon
Lee, Jacob
Joo, Eun-Jeong
Eom, Joong Sik
Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients
title Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients
title_full Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients
title_fullStr Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients
title_full_unstemmed Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients
title_short Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients
title_sort clinical effectiveness of intravenous peramivir versus oseltamivir for the treatment of influenza in hospitalized patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245436/
https://www.ncbi.nlm.nih.gov/pubmed/32547116
http://dx.doi.org/10.2147/IDR.S247421
work_keys_str_mv AT leejinseo clinicaleffectivenessofintravenousperamivirversusoseltamivirforthetreatmentofinfluenzainhospitalizedpatients
AT leemisuk clinicaleffectivenessofintravenousperamivirversusoseltamivirforthetreatmentofinfluenzainhospitalizedpatients
AT parkyoonseon clinicaleffectivenessofintravenousperamivirversusoseltamivirforthetreatmentofinfluenzainhospitalizedpatients
AT leejacob clinicaleffectivenessofintravenousperamivirversusoseltamivirforthetreatmentofinfluenzainhospitalizedpatients
AT jooeunjeong clinicaleffectivenessofintravenousperamivirversusoseltamivirforthetreatmentofinfluenzainhospitalizedpatients
AT eomjoongsik clinicaleffectivenessofintravenousperamivirversusoseltamivirforthetreatmentofinfluenzainhospitalizedpatients